PRMT7 at the crossroads of cancer progression and therapeutic targeting (Review).
- 1Department of Pharmaceutical Engineering, Chengdu University, Chengdu, Sichuan 610106, P.R. China.
- 2Department of Food Science and Engineering, Chengdu University, Chengdu, Sichuan 610106, P.R. China.
- 3Department of Ophthalmology, 474 Hospital of Urumqi, Urumqi, Xinjiang Uyghur Autonomous Region 830000, P.R. China.
Abstract
Protein arginine methyltransferase 7 (PRMT7), the sole type III PRMT family member, catalyzes arginine monomethylation and has recently emerged as an important regulator of cancer biology. Increasing evidence indicates that PRMT7 participates in tumor initiation and progression through epigenetic regulation, transcriptional control, RNA processing and signaling pathway modulation. Dysregulated PRMT7 expression has been reported in diverse malignancies, including leukemia, breast cancer, lung cancer, renal cell carcinoma, hepatocellular carcinoma, prostate cancer and gastric cancer. Functionally, PRMT7 has been implicated in epithelial‑mesenchymal transition, cancer stemness, metastasis and immune modulation, although its effects may vary depending on cellular and tumor context. The present review summarizes the structural and biochemical features of PRMT7, its mechanistic roles across different cancer types, and its potential as a therapeutic target. Recent progress in PRMT inhibitor development was also discussed, with particular emphasis on PRMT7‑selective compounds such as SGC3027, SGC8158 and JS1310, as well as the key challenges that remain for clinical translation. Elucidating the context‑specific functions and targetable vulnerabilities of PRMT7 may provide new opportunities for precision cancer therapy.
Related
- Editorial: E3 ubiquitin ligases: critical roles in cancer progression and therapeutic implications
- Box C/D SNORD116-17 promotes prostate cancer progression by targeting the miR-206/E2F5 axis
- ER‐Localized Deadenylase PNLDC1 Suppresses Colorectal Cancer Progression by Targeting the mRNA Decay of TUBB4B
- Targeting the SMG9–Wnt/β-catenin axis: A novel mechanism by which ginsenoside Rh2 suppresses triple-negative breast cancer progression
- Dynamic perturbation analysis: a modular rewiring framework for decoding cancer stage progression and identifying therapeutic vulnerabilities.
BibTeX
@article{he2026prmt7,
title = {{PRMT7 at the crossroads of cancer progression and therapeutic targeting (Review).}},
author = {Yuchen He and Jiayi Lou and Yijing Huang and Wen Deng and Xuehong Cai},
journal = {Oncology reports},
year = {2026},
month = oct,
doi = {10.3892/or.2026.9208},
url = {https://europepmc.org/article/MED/42852627},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - PRMT7 at the crossroads of cancer progression and therapeutic targeting (Review).
AU - Yuchen He
AU - Jiayi Lou
AU - Yijing Huang
AU - Wen Deng
AU - Xuehong Cai
PY - 2026
DA - 2026/10/09
JO - Oncology reports
DO - 10.3892/or.2026.9208
UR - https://europepmc.org/article/MED/42852627
AB - Protein arginine methyltransferase 7 (PRMT7), the sole type III PRMT family member, catalyzes arginine monomethylation and has recently emerged as an important regulator of cancer biology. Increasing evidence indicates that PRMT7 participates in tumor initiation and progression through epigenetic regulation, transcriptional control, RNA processing and signaling pathway modulation. Dysregulated PRMT7 expression has been reported in diverse malignancies, including leukemia, breast cancer, lung cancer, renal cell carcinoma, hepatocellular carcinoma, prostate cancer and gastric cancer. Functionally, PRMT7 has been implicated in epithelial‑mesenchymal transition, cancer stemness, metastasis and immune modulation, although its effects may vary depending on cellular and tumor context. The present review summarizes the structural and biochemical features of PRMT7, its mechanistic roles across different cancer types, and its potential as a therapeutic target. Recent progress in PRMT inhibitor development was also discussed, with particular emphasis on PRMT7‑selective compounds such as SGC3027, SGC8158 and JS1310, as well as the key challenges that remain for clinical translation. Elucidating the context‑specific functions and targetable vulnerabilities of PRMT7 may provide new opportunities for precision cancer therapy.
SN - 1021-335X
SN - 1791-2431
ER -